Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Chiara Fabbri; Ladislav Hosak; Rainald Mössner; Ina Giegling; Laura Mandelli; Frank Bellivier; Stephan Claes; David A. Collier; Alejo Corrales; Lynn E. Delisi; Carla Gallo; Michael Gill; James L. Kennedy; Marion Leboyer; Amanda Lisoway; Wolfgang Maier; Miguel Marquez; Isabelle Massat; Ole Mors; Pierandrea Muglia; Markus M. Nöthen; Michael C. O’Donovan; Jorge Ospina-Duque; Peter Propping; Yongyong Shi; David St Clair; Florence Thibaut; Sven Cichon; Julien Mendlewicz; Dan Rujescu; Alessandro Serretti

doi:10.1080/15622975.2016.1208843

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. Delisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea MugliaMarkus M. Nöthen, Michael C. O’Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu^*, Alessandro Serretti

^*Corresponding author for this work

Social Genetic & Developmental Psychiatry

Research output: Contribution to journal › Review article › peer-review

73 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

Original language	English
Pages (from-to)	5-28
Number of pages	24
Journal	World Journal of Biological Psychiatry
Volume	18
Issue number	1
DOIs	https://doi.org/10.1080/15622975.2016.1208843
Publication status	Published - 2 Jan 2017

Keywords

antidepressant
genetics-epigenetics
Major depression
transcriptomics-proteomics

Access to Document

10.1080/15622975.2016.1208843

Cite this

Fabbri, C., Hosak, L., Mössner, R., Giegling, I., Mandelli, L., Bellivier, F., Claes, S., Collier, D. A., Corrales, A., Delisi, L. E., Gallo, C., Gill, M., Kennedy, J. L., Leboyer, M., Lisoway, A., Maier, W., Marquez, M., Massat, I., Mors, O., ... Serretti, A. (2017). Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World Journal of Biological Psychiatry, 18(1), 5-28. https://doi.org/10.1080/15622975.2016.1208843

@article{7fd9a92479b247c59bbc7c764d61fd13,

title = "Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response",

abstract = "Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.",

keywords = "antidepressant, genetics-epigenetics, Major depression, transcriptomics-proteomics",

author = "Chiara Fabbri and Ladislav Hosak and Rainald M{\"o}ssner and Ina Giegling and Laura Mandelli and Frank Bellivier and Stephan Claes and Collier, {David A.} and Alejo Corrales and Delisi, {Lynn E.} and Carla Gallo and Michael Gill and Kennedy, {James L.} and Marion Leboyer and Amanda Lisoway and Wolfgang Maier and Miguel Marquez and Isabelle Massat and Ole Mors and Pierandrea Muglia and N{\"o}then, {Markus M.} and O{\textquoteright}Donovan, {Michael C.} and Jorge Ospina-Duque and Peter Propping and Yongyong Shi and {St Clair}, David and Florence Thibaut and Sven Cichon and Julien Mendlewicz and Dan Rujescu and Alessandro Serretti",

year = "2017",

month = jan,

day = "2",

doi = "10.1080/15622975.2016.1208843",

language = "English",

volume = "18",

pages = "5--28",

journal = "World Journal of Biological Psychiatry",

issn = "1562-2975",

publisher = "Taylor & Francis",

number = "1",

}

Fabbri, C, Hosak, L, Mössner, R, Giegling, I, Mandelli, L, Bellivier, F, Claes, S, Collier, DA, Corrales, A, Delisi, LE, Gallo, C, Gill, M, Kennedy, JL, Leboyer, M, Lisoway, A, Maier, W, Marquez, M, Massat, I, Mors, O, Muglia, P, Nöthen, MM, O’Donovan, MC, Ospina-Duque, J, Propping, P, Shi, Y, St Clair, D, Thibaut, F, Cichon, S, Mendlewicz, J, Rujescu, D & Serretti, A 2017, 'Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response', World Journal of Biological Psychiatry, vol. 18, no. 1, pp. 5-28. https://doi.org/10.1080/15622975.2016.1208843

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. / Fabbri, Chiara; Hosak, Ladislav; Mössner, Rainald et al.
In: World Journal of Biological Psychiatry, Vol. 18, No. 1, 02.01.2017, p. 5-28.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Consensus paper of the WFSBP Task Force on Genetics

T2 - Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

AU - Fabbri, Chiara

AU - Hosak, Ladislav

AU - Mössner, Rainald

AU - Giegling, Ina

AU - Mandelli, Laura

AU - Bellivier, Frank

AU - Claes, Stephan

AU - Collier, David A.

AU - Corrales, Alejo

AU - Delisi, Lynn E.

AU - Gallo, Carla

AU - Gill, Michael

AU - Kennedy, James L.

AU - Leboyer, Marion

AU - Lisoway, Amanda

AU - Maier, Wolfgang

AU - Marquez, Miguel

AU - Massat, Isabelle

AU - Mors, Ole

AU - Muglia, Pierandrea

AU - Nöthen, Markus M.

AU - O’Donovan, Michael C.

AU - Ospina-Duque, Jorge

AU - Propping, Peter

AU - Shi, Yongyong

AU - St Clair, David

AU - Thibaut, Florence

AU - Cichon, Sven

AU - Mendlewicz, Julien

AU - Rujescu, Dan

AU - Serretti, Alessandro

PY - 2017/1/2

Y1 - 2017/1/2

N2 - Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

AB - Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

KW - antidepressant

KW - genetics-epigenetics

KW - Major depression

KW - transcriptomics-proteomics

UR - http://www.scopus.com/inward/record.url?scp=84986183057&partnerID=8YFLogxK

U2 - 10.1080/15622975.2016.1208843

DO - 10.1080/15622975.2016.1208843

M3 - Review article

C2 - 27603714

AN - SCOPUS:84986183057

SN - 1562-2975

VL - 18

SP - 5

EP - 28

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

IS - 1

ER -

Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this